Novo Nordisk's Tale of Two Trials: A Paediatric Milestone Collides With a Cardiology Programme Unravelling

Novo Nordisk ends two Ziltivekimab heart failure trials, posts pediatric obesity win, and faces pricing pressures as shares fall 30% from January high.

The Danish pharmaceutical giant delivered a study in contrasts on a single day, announcing the premature termination of two late-stage cardiovascular trials while simultaneously reporting a paediatric obesity win for its flagship GLP-1 therapy. The juxtaposition captures the current predicament of a company whose core franchise keeps expanding even as its pipeline beyond metabolic disease narrows.

An independent data monitoring committee concluded that the two Ziltivekimab studies in heart failure patients were unlikely to yield results materially different from an earlier investigation that had already failed. Novo Nordisk acted on that assessment, halting both trials ahead of schedule. One study examining the drug in post-heart-attack patients continues, with readouts pencilled in for the first half of 2027.

The company flagged a non-cash impairment charge related to the drug's write-down for the third quarter of 2026, yet reaffirmed its guidance for adjusted operating profit this year. That a pipeline setback of this magnitude does not puncture near-term earnings expectations says something about the resilience of the underlying business — even if the share price tells a different story.

The stock has shed roughly 30 percent since touching a 52-week high of EUR 54.86 in late January, changing hands at EUR 38.56 and down more than 6 percent over the past month. The latest Ziltivekimab disappointment extends a run of pipeline reversals that has weighed on the shares for months, and market history suggests such headlines rarely pass without a reaction.

The Oral Pivot and Paediatric Potential

Investors are now recalibrating whether the commercial engine can offset the clinical setbacks. The oral Wegovy tablet launched in Germany just days ago — the first EU market to receive it — yet the stock has lost around 3.9 percent since, evidence that even constructive structural news is struggling to move the needle. In China, regulators have accepted the filing for the oral version of Wegovy, although Novo Nordisk has declined to offer a timeline for approval.

Those who assume the obesity franchise has reached maturity might examine the paediatric data more closely. In the STEP-Young study, 40.4 percent of children aged six to under twelve no longer met the criteria for obesity after 68 weeks, assuming full treatment adherence. The figure points to a demographic that extends well beyond the adult core business and hints at a potentially vast new market — regulatory hurdles notwithstanding.

US Pricing Pressures Reshape the Economics

The American pricing landscape is meanwhile undergoing a fundamental shift. Last November, Novo Nordisk committed to reducing prices for semaglutide-containing products including Wegovy and Ozempic across Medicare, Medicaid and a direct-to-patient distribution channel. Media reports indicate Ozempic and Wegovy would cost USD 350 per month through the TrumpRx channel, down from USD 1,000 and USD 1,350 respectively, with NovoLog and Tresiba available for USD 35 monthly.

The pricing concessions are a double-edged instrument: they secure market access but squeeze margins unless volume growth materialises as hoped. The competitive picture has sharpened further with the FDA granting Eli Lilly's Mounjaro approval to lower cardiovascular risk in high-risk type-2 diabetes patients — a move that intensifies pressure on Novo Nordisk's broader GLP-1 ambitions, according to Reuters.

A Structural Shift Beyond the Daily Charts

The deeper trend transcends any single trading session. The obesity and diabetes drug industry is navigating a pricing and access transformation while cardiovascular pipeline risks accumulate simultaneously. Novo Nordisk embodies that contradiction perhaps more vividly than any peer: considerable potential in its core franchise, tangible reversals in its expansion efforts.

Technical indicators reflect the underlying tension. The relative strength index sits at 40.5, with annualised volatility of 40 percent — metrics that capture the nervousness without dictating a direction. The shares trade roughly 29 percent below their January peak, and the distance to the 52-week low of EUR 30.25 has narrowed meaningfully.

Whether the market ultimately weights the structural substance — paediatric study results, market entries, pricing reforms — more heavily than the near-term pipeline disappointments remains an open question. The bull case rests on the oral tablet gaining traction among patients who prefer pills to injections, potentially delivering a growth spurt that eclipses the Ziltivekimab setback. The paediatric data opens a younger patient segment whose commercial value appears barely priced in, and a Chinese approval for the oral version would unlock an additional, potentially enormous market.

The bear case centres on the confluence of a thinning pipeline and intensifying competition. With Ziltivekimab out of the picture for heart failure, Novo Nordisk's reliance on semaglutide products deepens further. Eli Lilly's new cardiovascular indication for Mounjaro offers a differentiation that Novo Nordisk has yet to counter, and the US price cuts could prove corrosive to margins if the anticipated volume surge fails to arrive.

The next concrete catalyst is the outcome of the remaining Ziltivekimab study in post-heart-attack patients, expected in the first half of 2027. Until then, the shares will likely be judged primarily on sales figures for the oral Wegovy tablet — and on whether the company can convince the market that its growth narrative extends beyond the metabolic franchise that has defined it.